Acute promyelocytic leukemia pathophysiology: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Function}} | ! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Function}} | ||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Other Features}} | ! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Other Features}} | ||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
''PML'' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
15q24.1 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*A member of the tripartite motif (TRIM) family | |||
*Localizes to nucleolar bodies and functions as a transcription factor and tumor suppressor | |||
*Regulate p53 response to oncogenic growth signals | |||
*Influenced by the cell cycle | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Most common translocation | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | ||
| Line 42: | Line 54: | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
''NUMA'' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
11q13.4 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Contributes to a structural component of the nuclear matrix | |||
*Interacts with microtubules | |||
*Contributes to mitotic spindle formation during cell division | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Rare translocation | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
''STAT5B'' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
17q21.2 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*[[ | *Encodes a signal transducer and activator of transcription (STAT) | ||
* | *Serves an intracellular transduction molecule for cytokine signaling | ||
* | *Translocates to the nucleus and functions as a transcription factor | ||
*Involved in T cell receptor signaling | |||
*Involved in [[apoptosis]] | |||
*Sequesters the tumor suppressor ''ARF'' in the nucleus and protects ''ARF'' from degradation | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Rare translocation | |||
|- | |||
|} | |} | ||
Revision as of 21:54, 10 May 2018
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia pathophysiology |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Pathophysiology
The pathophysiology of acute promyelocytic leukemia begins with a balanced reciprocal chromosomal translocation in hematopoietic stem cells. The chromosomal translocation involves the juxtaposition of the retinoic acid receptor-alpha gene (RARA) on the long arm of chromosome 17 with another gene, most commonly the promyelocytic leukemia gene (PML) on the long arm of chromosome 15.[1] The translocation is designated as t(15;17)(q22;q12). The PML-RARA fusion product is a transcriptional regulator and prevents myeloid differentiation. This is known as a differentiation block, since the cells are unable to differentiate into normal mature cells. The result of the chromosomal translocation is ineffective blood cell production and uncontrolled proliferation of malignant promyelocytes.[1] In 95% of cases of acute promyelocytic leukemia, the translocation involved PML and RARA. However, it is important to note that RARA has multiple other binding partners which can lead to the development or acute promyelocytic leukemia.
Four other gene rearrangements have been described in APL fusing RARα to promyelocytic leukemia zinc finger (PLZF or ZBTB16), nucleophosmin (NPM), nuclear matrix associated (NUMA), or signal transducer and activator of transcription 5b (STAT5B) genes., ZBTB16
| Translocation Partner | Chromosomal Location | Function | Other Features |
|---|---|---|---|
|
PML |
15q24.1 |
|
|
|
PLZF (ZBTB16) |
11q23.2 |
|
|
|
NPM1 |
5q35.1 |
|
|
|
NUMA |
11q13.4 |
|
|
|
STAT5B |
17q21.2 |
|
|
References
- ↑ 1.0 1.1 Langabeer SE, Preston L, Kelly J, Goodyer M, Elhassadi E, Hayat A (2017). "Molecular Profiling: A Case of ZBTB16-RARA Acute Promyelocytic Leukemia". Case Rep Hematol. 2017: 7657393. doi:10.1155/2017/7657393. PMC 5424191. PMID 28529810.